New potential Parvo Treatment
Monoclonal antibodies have been in the news a lot with the COVID pandemic and their usefulness in treating disease.
Elanco (a large animal pharma company) announced purchase of the monoclonal antibody treatment for Parvo.
The only treatment we have had for this disease has been supportive in nature: fluid support, antibiotics and some have tried anti-virals with mixed success. This could be a game changer.
Doug, DVM
Elanco (a large animal pharma company) announced purchase of the monoclonal antibody treatment for Parvo.
“With parvovirus on the rise, it’s more important than ever to bring a new treatment option to veterinarians for this devastating and deadly disease,” says Aaron Schacht, Elanco’s executive vice president of innovation, regulatory, and business development. “We’re excited to establish this important partnership with KindredBio to develop and commercialize this novel monoclonal antibody.”
KIND-030 is currently being pursued for two indications in dogs: prophylactic therapy to prevent clinical signs of CPV infection and treatment of established parvovirus infection. Completion of an upcoming pivotal efficacy study for the therapeutic indication is expected in the first quarter of 2021, Elanco says.
A study conducted by Kindred Biosciences earlier this year demonstrated 100 percent efficacy in the prevention of CPV, as well as a mortality benefit in the treated group
The only treatment we have had for this disease has been supportive in nature: fluid support, antibiotics and some have tried anti-virals with mixed success. This could be a game changer.
Doug, DVM
